1. Landon-Cardinal O, Allenbach Y, Soulages A, Rigolet A, Hervier B, Champtiaux N, et al. Rituximab in the treatment of refractory anti-HMGCR immune-mediated necrotizing myopathy.
J Rheumatol 2019;46:623-627.
2. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis.
J Rheumatol 2006;33:1021-1026.
3. Mendell JR, Rodino‐Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy.
Ann Neurol 2013;74:637-647.
4. Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy.
Neurology 2020;94:e2270-e2282.
5. Dahl TH. International classification of functioning, disability and health: an introduction and discussion of its potential impact on rehabilitation services and research.
J Rehabil Med 2002;34:201-204.
6. Rosenfeld J, Jackson CE. Neuromuscular disorders in clinical practice. Boston: Butterworth-Heinemann, 2002;316-317.
7. Stein F, Cutler SK. Clinical research in allied health and special education. San Diego: Singular Publishing Group, 1996.
8. Brigadier G, Riddoch M, Brigadier W, Rowley-Bristow M, Brigadier H. Aids to the examination of the peripheral nervous system. London: Crown Copyright, 1943;70.
9. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol.
Muscle Nerve 1981;4:186-197.
10. Scott O, Hyde S, Goddard C, Dubowitz V. Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy.
Muscle Nerve 1982;5:291-301.
11. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands.
Neuromuscul Disord 2004;14:337-345.
12. Escolar D, Henricson EK, Mayhew J, Florence J, Leshner R, Patel K, et al. Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children.
Muscle Nerve 2001;24:787-793.
13. Merlini L, Mazzone ES, Solari A, Morandi L. Reliability of hand‐held dynamometry in spinal muscular atrophy.
Muscle Nerve 2002;26:64-70.
14. Stuberg WA, Metcalf W. Reliability of quantitative muscle testing in healthy children and in children with Duchenne muscular dystrophy using a hand-held dynamometer.
Phys Ther 1988;68:977-982.
15. Bohannon RW. Intertester reliability of hand-held dynamometry: a concise summary of published research.
Percept Mot Skills 1999;88:899-902.
16. Bushby K, Connor E. Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings.
Clin Investig 2011;1:1217-1235.
17. MacKenzie CR, Charlson ME. Standards for the use of ordinal scales in clinical trials.
Br Med J (Clin Res Ed) 1986;292:40-43.
18. Vignos PJ, Spencer GE, Archibald KC. Management of progressive muscular dystrophy of childhood.
JAMA 1963;184:89-96.
19. Fanin M, Angelini C. Muscle pathology in dysferlin deficiency.
Neuropathol Appl Neurobiol 2002;28:461-470.
20. Mathieu J, Boivin H, Meunier D, Gaudreault M, Begin P. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy.
Neurology 2001;56:336-340.
21. Bérard C, Payan C, Hodgkinson I, Fermanian J; MFM Collaborative Study Group. A motor function measure scale for neuromuscular diseases. Construction and validation study.
Neuromuscul Disord 2005;15:463-470.
22. Mercuri E, Coratti G, Messina S, Ricotti V, Baranello G, D’Amico A, et al. Revised North Star Ambulatory Assessment for young boys with Duchenne muscular dystrophy.
PLoS One 2016;11:e0160195.
23. Ramsey D, Scoto M, Mayhew A, Main M, Mazzone ES, Montes J, et al. Revised Hammersmith Scale for spinal muscular atrophy: a SMA specific clinical outcome assessment tool.
PLoS One 2017;12:e0172346.
24. Harris E, Bladen CL, Mayhew A, James M, Bettinson K, Moore U, et al. The clinical outcome study for dysferlinopathy: an international multicenter study.
Neurol Genet 2016;2:e89.
25. Harris‐Love MO, Joe G, Davenport TE, Koziol D, Abbett Rose K, Shrader JA, et al. Reliability of the adult myopathy assessment tool in individuals with myositis.
Arthritis Care Res 2015;67:563-570.
26. Jackson C, Barohn R, Gronseth G, Pandya S, Herbelin L, Group MS. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity.
Muscle Nerve 2008;37:473-476.
27. Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, Young SD, et al. Revised upper limb module for spinal muscular atrophy: development of a new module.
Muscle Nerve 2017;55:869-874.
28. Pane M, Mazzone ES, Fanelli L, De Sanctis R, Bianco F, Sivo S, et al. Reliability of the performance of upper limb assessment in Duchenne muscular dystrophy.
Neuromuscul Disord 2014;24:201-206.
29. Florence JM, Pandya S, King WM, Robison JD, Signore LC, Wentzell M, et al. Clinical trials in Duchenne dystrophy: standardization and reliability of evaluation procedures.
Phys Ther 1984;64:41-45.
30. Mayhew JE, Florence JM, Mayhew TP, Henricson EK, Leshner RT, McCarter RJ, et al. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy.
Muscle Nerve 2007;35:36-42.
31. Beenakker EA, Maurits NM, Fock JM, Brouwer OF, van der Hoeven JH. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients.
Eur J Paediatr Neurol 2005;9:387-393.
32. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, et al. The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy.
Muscle Nerve 2010;41:500-510.
33. Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.
Pediatrics 2009;123:229-240.
34. Li D, McDonald CM, Elfring GL, Souza M, McIntosh J, Kim DH, et al. Assessment of treatment effect with multiple outcomes in 2 clinical trials of patients with Duchenne muscular dystrophy.
JAMA Net Open 2020;3:e1921306.
35. Kingsley C, Patel S. Patient-reported outcome measures and patient-reported experience measures.
Bja Education 2017;17:137-144.
36. Brazier JE, Harper R, Jones N, O’cathain A, Thomas K, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care.
BMJ 1992;305:160-164.
37. Vincent K, Carr A, Walburn J, Scott D, Rose M. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL).
Neurology 2007;68:1051-1057.
38. Sansone V, Panzeri M, Montanari M, Apolone G, Gandossini S, Rose M, et al. Italian validation of INQoL, a quality of life questionnaire for adults with muscle diseases.
Euro J Neurol 2010;17:1178-1187.
39. Seesing FM, van Vught LE, Rose MR, Drost G, van Engelen BG, van der Wilt GJ. The individualized neuromuscular quality of life questionnaire: cultural translation and psychometric validation for the Dutch population.
Muscle Nerve 2015;51:496-500.
40. Fujino H, Saito T, Takahashi MP, Takada H, Nakayama T, Ogata K, et al. Validation of the individualized neuromuscular quality of life in Japanese patients with myotonic dystrophy.
Muscle Nerve 2018;58:56-63.